Nypro to make Ventaira's new asthma inhaler
moulding, has been contracted to manufacture Ventaira's new
pulmonary drug delivery device.
Ventaira is a specialty pharma company focused on developing new or existing drugs for inhalation using its unique liquid aerosol technology called electrohydrodynamic (EHD), that the company claims can deliver respiratory and systemically active drugs to the lung more efficiently and effectively.
The first of Ventaira's new drug/device products, an inhaled formulation of the asthma corticosteriod, fluticosone, which Ventaira has named Acuair, will enter Phase II trials in the third quarter of this year.
Nypro, with considerable experience in inhalation devices manufacturing, will make the inhalation device for this trial and provides the capability to quickly scale up production as needed in every stage of clinical development.
The new formulation of the asthma drug is being manufactured elsewhere.
"Our inhalation device, which is based on our proprietary EHD technology, has the potential to be a next-generation pulmonary delivery tool that will provide patients with an efficient and easy solution for administering their inhaled medications," said Leslie Williams, President and CEO of Ventaira.
According to Williams, the device will deliver the drug in a consistent dose with 80 per cent accuracy, compared to current devices that are inefficient in delivering an adequate dose, with only 10-15 per cent of the drug getting into the lungs.
"It is likely that Nypro will continue to make the device when the product eventually reaches commercialisation," Williams told Outsourcing-Pharma.com.
"We also have a number of other compounds for pain and other systemic applications coming through the pipeline and it is likely that within a year or two Nypro will also be contracted to manufacture the devices for the clinical development of these products also," she said.
